Vigil Neuroscience (VIGL) Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP Jun 4, 2025 07:00AM
Stifel Downgrades Vigil Neuroscience Inc (VIGL) to Hold Following Takeover May 27, 2025 05:02PM
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Vigil Neuroscience, Inc. Buyout May 23, 2025 02:55PM
Mizuho Downgrades Vigil Neuroscience Inc (VIGL) to Neutral May 23, 2025 01:09AM
Jefferies Downgrades Vigil Neuroscience Inc (VIGL) to Hold May 22, 2025 01:19PM


May 22, 2025 08:35AM Guggenheim Downgrades Vigil Neuroscience Inc (VIGL) to Neutral
May 22, 2025 07:43AM Stifel Reiterates Buy Rating on Vigil Neuroscience Inc (VIGL)
May 22, 2025 05:29AM William Blair Downgrades Vigil Neuroscience Inc (VIGL) to Market Perform
May 22, 2025 02:51AM Citizens JMP Downgrades Vigil Neuroscience Inc (VIGL) to Market Perform
May 21, 2025 07:23PM Sanofi (SNY) to acquire Vigil Neuroscience
Apr 2, 2025 07:01AM Vigil Neuroscience (VIGL) Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference
Mar 31, 2025 07:48AM Vigil Neuroscience (VIGL) Files for 5.38M Share Offering by Selling Stockholders
Mar 17, 2025 06:40AM Vigil Neuroscience Inc (VIGL) PT Lowered to $14 at H.C. Wainwright
Mar 13, 2025 04:32PM Vigil Neuroscience, Inc. (VIGL) Misses Q4 EPS by 3c
Mar 13, 2025 10:03AM Stifel Reiterates Buy Rating on Vigil Neuroscience Inc (VIGL)
Jan 23, 2025 07:00AM Vigil Neuroscience (VIGL) Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927
Dec 4, 2024 05:49AM William Blair Starts Vigil Neuroscience Inc (VIGL) at Outperform
Nov 26, 2024 06:03AM Guggenheim Reiterates Buy Rating on Vigil Neuroscience Inc (VIGL)
Oct 9, 2024 09:04AM JMP Securities Reiterates Market Outperform Rating on Vigil Neuroscience Inc (VIGL)
Sep 19, 2024 06:54AM Mizuho Reiterates Outperform Rating on Vigil Neuroscience Inc (VIGL)
Sep 17, 2024 07:00AM Vigil Neuroscience (VIGL) Announces FDA Removed Partial Clinical Hold on VG-3927
Aug 15, 2024 07:56AM Stifel Reiterates Buy Rating on Vigil Neuroscience Inc (VIGL)
Aug 13, 2024 07:48AM Vigil Neuroscience, Inc. (VIGL) Tops Q2 EPS by 3c
Jul 24, 2024 07:00AM Vigil Neuroscience (VIGL) Reports Interim Data from Ongoing Phase 1 Clinical Trial of VG-3927
Jul 19, 2024 06:06AM Vigil Neuroscience Inc (VIGL) PT Lowered to $17 at H.C. Wainwright
Jul 18, 2024 02:37PM Mizuho Reiterates Outperform Rating on Vigil Neuroscience Inc (VIGL)
Jul 18, 2024 07:01AM Vigil Neuroscience (VIGL) Provides Update on Clinical Development Strategy
Jun 28, 2024 06:42AM H.C. Wainwright Reiterates Buy Rating on Vigil Neuroscience Inc (VIGL)
Jun 27, 2024 05:40AM Vigil Neuroscience (VIGL) Announces $40M Investment from Sanofi (SNY) at $7.44/sh